Leading the way to safer medication
 Crosscheck  Recommender

Adalimumab

Description

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).

ATC Classification

Code
Title
Category
L04AB04
Adalimumab
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

Trade names

Trade name
Countries
AMGEVITA

Australia Austria Cyprus France Netherlands

AMSPARITY

Austria

HADLIMA

Australia

HALIMATOZ

Austria

HEFIYA

Austria

HULIO

Austria France Netherlands

HUMIRA

Australia Austria Canada Cyprus France

HYRIMOZ

Australia Austria Cyprus France Netherlands

IDACIO

Australia Austria Cyprus France Netherlands

IMRALDI

Austria Cyprus France Netherlands

Product Monographs

Monograph
Type
Country
HUMIRA 40mg/0.4ml Solution for injection in pre-filled syringe / pen
MPI, EU: SmPC
HUMIRA 40mg/0.8ml Solution for injection
MPI, EU: SmPC
HUMIRA 40mg/0.8ml Solution for injection in pre-filled syringe / pen
MPI, EU: SmPC
HUMIRA 20mg Solution for injection in pre-filled syringe
MPI, EU: SmPC
HUMIRA 80mg Solution for injection in pre-filled syringe / pen
MPI, EU: SmPC

2D Molecule Structure

Unique Ingredient Identifier (UNII)

FYS6T7F842 - ADALIMUMAB

CAS Registry Number

331731-18-1 - adalimumab

SNOMED-CT

407317001 - Adalimumab (substance)

 
Next: Usage >